Therefore, further clinical studies are necessary to evaluate the efficacy and safety of anti-TNF-α in the treatment of AIH.240 Encouragingly, low-dose recombinant IL-2 was shown to improve Treg cells and clinical and biochemical parameters with minimal side effects in 2 AIH patients.241 This makes it possible to target Tregs, while more studies addressing how to increase the specificity and persistence of IL-2-stimulated Tregs are needed. The gene discussed is TNF; the disease is autoimmune hepatitis.